Cognitive Training for Alzheimer's Disease
(PACT Trial)
Trial Summary
The trial excludes participants who are using medications typically prescribed for dementia, such as Namenda, Memantine, and Donepezil. If you are taking these medications, you would not be eligible to participate.
Research shows that computer-based cognitive training can help improve cognitive function in older adults with mild cognitive impairment and may delay the progression of cognitive decline in Alzheimer's patients. Studies have also found that such training is beneficial in neurological rehabilitation, particularly for attention deficits.
12345Research indicates that computerized cognitive training is generally safe for older adults, including those with mild cognitive impairment or dementia. It has been used effectively in neurological rehabilitation without significant safety concerns.
16789Cognitive Training for Alzheimer's is unique because it uses computer-based exercises to target specific brain functions and improve cognitive abilities through neuroplasticity (the brain's ability to reorganize itself). Unlike traditional drug treatments, this approach leverages technology to create engaging and adaptive exercises that can be tailored to individual needs, potentially enhancing motivation and treatment engagement.
12101112Eligibility Criteria
This trial is for individuals aged 65 or older with no signs of Mild Cognitive Impairment (MCI) or dementia, as indicated by a Montreal Cognitive Assessment score >=26. Participants must be able to perform computer exercises and have good mental health without severe depression. They should not be on dementia medications nor have completed similar cognitive training recently.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants complete computerized cognitive training with 25 initial sessions over 3 to 5 months, followed by booster sessions at 1 and 2 years
Booster Sessions
Participants complete 10 additional sessions of training at 1-year and 2-years
Follow-up
Participants are monitored for incidence of mild cognitive impairment or dementia